G protein-coupled receptors (GPCRs) are regulated by multiple families of kinases including GPCR kinases (GRKs). GRK4 is constitutively active towards GPCRs, and polymorphisms of GRK4γ are linked to hypertension. We examined, through co-immunoprecipitation, the interactions between GRK4γ and the Gα and Gβ subunits of heterotrimeric G proteins. Because GRK4 has been shown to inhibit Gα s -coupled GPCR signaling and lacks a PH domain, we hypothesized that GRK4γ would interact with active Gα s , but not Gβ. Surprisingly, GRK4γ preferentially interacts with inactive Gα s and Gβ to a greater extent than active Gα s . GRK4γ also interacts with inactive Gα 13 and Gβ. Functional studies demonstrate that wild-type GRK4γ, but not kinase-dead GRK4γ, ablates isoproterenol-mediated cAMP production indicating that the kinase domain is responsible for GPCR regulation. This evidence suggests that binding to inactive Gα s and Gβ may explain the constitutive activity of GRK4γ towards Gα s coupled receptors.G protein-coupled receptor kinases (GRKs) comprise a family of seven proteins that possess an amino terminal regulator of G protein signaling homology (RH) domain and a serine/ threonine kinase domain similar to protein kinase C [1]. GRKs initiate homologous desensitization through phosphorylation of the third cytoplasmic loop or carboxy terminus of ligand bound/activated target receptors [1]. This desensitization of the activated receptor is crucial in regulating signal transduction as well as ligand-mediated receptor endocytosis. The GRK1-like family, GRK1 and GRK7, are found in rod and cone cells and are associated with opsins [2]; the GRK2-like family, GRK2 and GRK3 (also known as β-adrenergic receptor kinase 1 and 2, respectively), are ubiquitously expressed and associate with Gα q/11 -coupled receptors [1]; and finally, the GRK4-like family comprises GRK4, GRK5, and GRK6, which compared to the other GRKs little is known about their biology [3]. GRK5 and GRK6 are expressed in multiple tissues [1], whereas GRK4 is expressed in the testis [4], kidney tubular cells [5], brain [6], and myometrium [7]. In this study we focused on GRK4.GRK4 was first identified during positional cloning of the Huntington's disease locus [8]. Early in vitro studies demonstrated that GRK4 phosphorylates the β 2 -adrenergic receptor (β 2 AR) in a PIP 2 -dependent manner [4]. Additionally, both GRK4 and GRK2, significantly decrease luteinizing hormone/chorionic gonadotropin receptor-mediated cAMP production [4]. These